InfuSystem Holdings, Inc. (INFU) Income Statement

The trajectory is one of sequential slowdown: growth printed above 6% in every quarter of 2024, drifted to the 3-7% range through 2025, and turned negative in 2026Q1 before a modest 2.6% recovery in 2026Q2. Because quarterly revenue has oscillated in a fairly tight $32-37M band for two years, investors should treat the pattern as a plateau rather than a scalable growth engine, and probe whether the deceleration reflects softer procedure volumes, contract timing, or a mix shift toward lower-growth service lines. Any renewed multiple expansion likely depends on re-acceleration that the last four quarters do not yet evidence.

The margin gain is structurally credible rather than cosmetic: COGS has remained in a narrow $15.5-17.0M corridor across all ten quarters while revenue grew, which implies real efficiency in equipment servicing, supply chain, or a favorable shift toward higher-margin service revenue. Notably, the margin did not revert during the 2025Q1 and 2026Q1 revenue dips, suggesting the improvement is embedded in cost structure rather than purely volume-driven operating leverage. The analytical question is durability versus the 55-58% band observed over the last six quarters; further expansion may be limited unless pricing power improves, so investors should monitor whether 58% proves a ceiling.

SG&A has fluctuated between $14.6M and $18.3M without a clear upward trend, meaning incremental gross profit has largely converted to operating income rather than being consumed by overhead growth — the primary source of the swing from a -2.6% to an 11.2% operating margin. However, the conversion is not perfectly consistent: 2025Q1 and 2026Q1 each saw SG&A spikes to $18.3M and $17.9M that crushed operating margin to 1.8% and 4.7% respectively, which hints at seasonal or event-driven expense variability investors should track. Absent another step-up in operating expenses, the current setup implies further incremental margin if revenue re-accelerates, but the Q1 pattern cautions against extrapolating peak-quarter margins across the year.

This inflection is defined by a rare combination of rising revenue and falling absolute COGS, which suggests a discrete change — potentially contract renegotiation, equipment sourcing improvements, or mix — rather than gradual trend improvement. The lasting impact is that every quarter since 2024Q3 has generated positive operating income, versus a loss-making first quarter in both 2024 and 2025, indicating the change appears to have been structural. The durability of this regime is the single most important underwriting question, as the 850 basis points of margin expansion since then is the entire basis for InfuSystem's equity story.